P1NP	
Description	P1NP (procollagen type 1 N-terminal-propeptide) is a specific indicator of type 1 collagen deposition and thus may be defined as a true bone formation marker. P1NP is released during collagen maturation and moves into the bloodstream were it exists in both the monomeric and trimeric forms.
Indication	P1NP reflects osteoblast activity so any disease increasing the activity of osteoblasts or activation frequency of the bone forming unit will result in elevated P1NP concentrations. Low P1NP may indicate adynamic bone. P1NP is intended for use in monitoring anti-resorptive therapy following the diagnosis of osteoporosis, in post-menopausal women and in patients diagnosed with Paget's disease of the bone.
Additional Info	P1NP is measured using a total immunoassay method therefore quantifies both the trimeric and momeric fractions. Clearance of monomeric P1NP has been shown to be lower in patients with severe renal impairment therefore elevating the P1NP result.
Concurrent Tests	Total ALP
Dietary Requirements	None. P1NP shows minimal circadian rhythm or seasonal variation and food intake or diet show no detectable influence on serum levels. A baseline pre-treatment measurement is required if assessing response to anti-resorption therapy.
Interpretation	Pre-menopausal Females 30 - 78 μg/L Post-menopausal Females 26 -110 μg/L Males 20 -76 μg/L
Collection Conditions	No specific collection requirements.
Frequency of testing	N/A

Version: 1.0 Date: 28/07/15

Document agreed by: V Mishra